Clenbuterol upregulates histone demethylase JHDM2a via the β2-adrenoceptor/cAMP/PKA/p-CREB signaling pathway

State Key Laboratory for Agrobiotechnology, China Agricultural University, Beijing 100193, China.
Cellular Signalling (Impact Factor: 4.32). 07/2012; 24(12):2297-306. DOI: 10.1016/j.cellsig.2012.07.010
Source: PubMed


β(2)-Adrenergic receptor (β(2)-AR) signaling activated by the agonist clenbuterol is important in the metabolism of muscle and adipose cells. Additionally, the significant role of histone demethylase JHDM2a in regulating metabolic gene expression was also recently demonstrated in Jhdm2a(-/-) mice. To elucidate the molecular mechanism involved in clenbuterol-induced adipocyte reduction from an epigenetic perspective, this study focused on cAMP-responsive element binding protein (CREB) to determine whether JHDM2a is regulated by the β(2)-AR/cAMP/protein kinase A (PKA) signaling pathway.
In porcine tissues treated with clenbuterol, JHDM2a expression was upregulated, and in porcine cells, expression of exogenous CREB led to increased JHDM2a expression. In addition, changes in JHDM2a expression were coincident with variations in the phosphorylation of CREB and p-CREB/CBP interaction in porcine and human cells treated with drugs known to modify the β(2)-AR/cAMP/PKA pathway. Finally, binding assays demonstrated that CREB regulated JHDM2a by binding directly to the CRE site nearest to the transcription start site.
Our results reveal that clenbuterol activates the β(2)-AR signaling pathway upstream of JHDM2a and that CREB acts as an intermediate link regulated by cAMP-PKA to induce activity of the JHDM2a promoter. These findings suggest that clenbuterol decreases adipose cell size and increases muscle fiber size in porcine tissues by virtue of JHDM2a-mediated demethylation, which regulates downstream metabolic and related genes.

14 Reads
    • "Accumulating evidence suggests that epigenetic mechanisms are engaged during synaptic plasticity, learning, and memory (Levenson et al., 2004; Chwang et al., 2006; Levenson et al., 2006; Gupta et al., 2010; Kramer et al., 2011; Monsey et al., 2011; Biergans et al., 2012). Recent evidence in non-neuronal tissue has indicated a putative interaction between noradrenergic receptor stimulation and epigenetic regulation of transcription (Ha et al., 2010; Haworth et al., 2012; Li et al., 2012; Chang et al., 2013). To investigate a role for regulation of the epigenome following NE-modulated hippocampal LTP, we probed several key epigenetic modifications including DNA methylation, histone acetylation and histone phosphorylation in response to NE+100 Hz stimulation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Norepinephrine (NE) is a neuromodulator that can effect long-lasting changes in synaptic strength such as long-term potentiation (LTP), a putative cellular mechanism for memory formation in the mammalian brain. Persistent LTP requires alterations in gene expression that may involve epigenetic mechanisms such as DNA methylation, histone acetylation, and histone phosphorylation. It is known that beta-adrenergic receptors and NE can boost LTP maintenance by regulating translation. However, it is unclear whether NE can additionally engage epigenetic mechanisms to regulate transcription and boost LTP endurance. To address this issue, we probed NE-treated mouse hippocampal slices with pharmacological inhibitors targeting epigenetic regulatory pathways and discovered that NE activates beta-adrenergic receptors to boost LTP maintenance in area CA1 through DNA methylation and post-translational histone modifications. Specifically, NE paired with 100-Hz stimulation enhanced histone H3 acetylation and phosphorylation, both of which were required for NE-induced boosting of LTP maintenance. Together, our findings identify NE as a neuromodulatory transmitter capable of triggering epigenetic, transcriptional control of genes required for establishing persistent LTP in the mouse hippocampus. These modifications may contribute to the stabilization of memory. This article is protected by copyright. All rights reserved.
    The Journal of Physiology 11/2015; DOI:10.1113/JP271432 · 5.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AGR syndrome (the clinical triad of Aniridia, Genitourinary anomalies and mental Retardation, a subgroup of WAGR syndrome for Wilms tumor, Aniridia, Genitourinary anomalies and mental Retardation) is a rare syndrome caused by a contiguous gene deletion in the 11p13-14 region. However, the mechanisms of WAGR syndrome pathogenesis are elusive. In this study, we provide evidence that LGR4 (also named GPR48), the only G-protein coupled receptor (GPCR) gene in the human chromosome 11p12-11p14.4 fragment, is the key gene responsible for the diseases of AGR syndrome. Deletion of Lgr4 in mouse led to aniridia, polycystic kidney disease, genitourinary anomalies, and mental retardation, similar to the pathological defects of AGR syndrome. Furthermore, Lgr4 inactivation significantly increased cell apoptosis and decreased the expression of multiple important genes involved in the development of WAGR syndrome related organs. Specifically, deletion of Lgr4 down-regulated the expression of histone demethylases Jmjd2a and Fbxl10 through cAMP-CREB signaling pathways both in mouse embryonic fibroblast cells and in urinary and reproductive system mouse tissues. Our data suggest that Lgr4, which regulates eye, kidney, testis, ovary, and uterine organ development as well as mental development through genetic and epigenetic surveillance, is a novel candidate gene for the pathogenesis of AGR syndrome.
    Journal of Biological Chemistry 02/2014; 289(13). DOI:10.1074/jbc.M113.530816 · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rett syndrome is a severe childhood onset neurodevelopmental disorder caused by mutations in methyl-CpG-binding protein 2 (MECP2), with known disturbances in catecholamine synthesis. Here, we show that treatment with the β2-adrenergic receptor agonist clenbuterol increases survival, rescues abnormalities in respiratory function and social recognition, and improves motor coordination in young male Mecp2-null (Mecp2(-/y)) mice. Importantly, we demonstrate that short-term treatment with clenbuterol in older symptomatic female heterozygous (Mecp2(-/+)) mice rescues respiratory, cognitive, and motor coordination deficits, and induces an anxiolytic effect. In addition, we reveal abnormalities in a microRNA-mediated pathway, downstream of brain-derived neurotrophic factor that affects insulin-like growth factor 1 (IGF1) expression in Mecp2(-/y) mice, and show that treatment with clenbuterol restores the observed molecular alterations. Finally, cotreatment with clenbuterol and recombinant human IGF1 results in additional increases in survival in male null mice. Collectively, our data support a role for IGF1 and other growth factor deficits as an underlying mechanism of Rett syndrome and introduce β2-adrenergic receptor agonists as potential therapeutic agents for the treatment of the disorder.
    Proceedings of the National Academy of Sciences 06/2014; 111(27). DOI:10.1073/pnas.1309426111 · 9.67 Impact Factor
Show more